Amyl Nitrite

PreclinicalSmall molecule

JJohns Hopkins University

Amyl Nitrite is one of 6 small molecule programs targeting Achalasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AchalasiaActive, not recruiting

AchalasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Achalasia

#DrugCompanyPhaseTrials

Avycaz

PPhiladelphia Eye Associates

Myrbetriq

1 3

Botox

RRevance Therapeutics, Inc.

Preclinical

2 4

Olinciguat

CCyclerion Therapeutics

Phase 2

1 5

Second Generation Cephalosporin

SShanghai Zhongshan Hospital

Preclinical

1 6

Amyl Nitrite

JJohns Hopkins University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Achalasia1 trial

Diagnostic Utility of Amyl Nitrite in Patients With Suspected Achalasia Undergoing High Resolution Esophageal Manometry (HREM)

Withdrawn·JJohns Hopkins University·N/A·NCT02428959

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amyl Nitrite. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amyl Nitrite compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amyl Nitrite. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJohns Hopkins University

Amyl Nitrite

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Achalasia1 trial

References

Drug Info

Quick Facts

Related News